Clinical Trial Update: Intranasal Oxytocin in Hypothalamic Obesity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating intranasal oxytocin for hypothalamic obesity associated with craniopharyngioma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma
• Hypothalamic Obesity

Drugs mentioned

• intranasal oxytocin (oxytocin)

Snippet

Sponsor: Shana McCormack, MD | Conditions: Craniopharyngioma, Hypothalamic Obesity | Phase 2 | Status: COMPLETED | Results posted: 2022-10-05